In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kevin Grogan

Managing Editor, Europe

Manchester, UK

Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.

Latest From Kevin Grogan

AstraZeneca Cultivates Oncology Pipeline With Pinetree Pact

Deal Snapshot: Degrading rather than inhibiting a target protein has emerged as one of the most promising approaches in drug discovery and AstraZeneca is paying handsomely to advance its presence in the space.

Deals Cancer

Almirall Pleased With Promising Start For Ebglyss

The Barcelona-headquartered group’s Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and reimbursement has just been secured in the UK.

Sales & Earnings Dermatology

Narasimhan Playing The Long Game At Novartis

The head of the Basel-headquartered giant is no fan of bidding wars when it comes to dealmaking. "If we are outbid and it’s not within our envelope, we just walk away and we’re okay with that.”

Business Strategies Commercial

Cosentyx Delivers Again For Novartis With Hidradenitis Suppurativa Launch

Two older drugs – Cosentyx and Entresto – continue to drive growth at the Swiss giant, while Leqvio is finally making its mark on the sales front.

Sales & Earnings Business Strategies

Tackling The Challenge Of Malaria Clinical Trials In Africa

Novartis leads the fight against malaria, pioneering innovative studies in sub-Saharan Africa to combat parasite resistance to current antimalarials.

Vaccines Rwanda

ASCO Data Are Catalyst For CatalYm Cash Boost

The German biotech has unveiled a $150m series D financing round to support a “broad Phase IIb development program for visugromab” and explore its potential to induce cancer remission depth and durability across multiple solid tumor indications.

Financing ImmunoOncology
See All
UsernamePublicRestriction

Register